Syncom Formulations India Ltd Stock Price Today (NSE: SYNCOMF)
Fundamental Score
Syncom Formulations India Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Syncom Formulations India Ltd share price today is ₹13.67, up +0.00% on NSE/BSE as of 17 February 2026. Syncom Formulations India Ltd (SYNCOMF) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹1.46K (Cr). The 52-week high for SYNCOMF share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 23.28x, SYNCOMF is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 15.50% and a debt-to-equity ratio of 0.00.
Syncom Formulations India Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Syncom Formulations India Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Syncom Formulations Share Price: A Financial Stability Analysis
The pharmaceutical industry faces increasing pricing pressures and regulatory scrutiny, requiring companies to demonstrate efficiency and innovation to maintain profitability. This analysis examines the financial stability of Syncom Formulations India Ltd., focusing on its current trading price and key financial metrics. The current Syncom Formulations share price stands at ₹13.65, with a Price-to-Earnings (PE) ratio of 23.28 and a Return on Capital Employed (ROCE) of 18.59%. This report is part of a comprehensive 80-parameter fundamental audit verified by Sweta Mishra.
The PE ratio of 23.28 suggests that investors are willing to pay ₹23.28 for every rupee of Syncom Formulation's earnings. While this figure appears reasonable, it is crucial to compare it with its sector peers. Comparing Syncom Formulations India Ltd. to a peer like
Mankind Pharma Ltd reveals a disparity in market perception, possibly due to differences in management quality and brand recognition. Mankind Pharma Ltd., with its established brand and strong management team, often commands a higher PE ratio. Such observations suggest areas of Syncom where improvements could lead to re-evaluation of valuation.Syncom Formulations' ROCE of 18.59% warrants further investigation. ROCE measures how efficiently a company is using its capital to generate profits. An ROCE exceeding the company's cost of capital indicates value creation. In this case, the 18.59% ROCE suggests that Syncom is effectively deploying its capital and generating returns. A consistently high ROCE strengthens a company's moat, the ability to protect its profits from competitors. This figure implies that Syncom possesses a competitive advantage, potentially driven by manufacturing efficiencies or niche product offerings.
This analysis provides a snapshot of Syncom Formulations' financial standing based on readily available data. Further due diligence, including a thorough examination of the company's balance sheet, cash flow statement, and competitive landscape, is necessary for a more complete understanding of its financial stability and future prospects. Note that this is an observational analysis and does not constitute financial advice. No buy or sell recommendations are implied.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Syncom Formulations India Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SYNCOMF across key market metrics for learning purposes.
Positive Indicators
12 factors identified
Strong Return on Equity (15.50%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (18.59%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Attractive Valuation (P/E: 23.28 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (53.79%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (19.66%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (17.51% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (23.05% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (27.71% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (105.39x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (50.57%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
3 factors identified
Negative Free Cash Flow (₹-10.56 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 0.10%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Syncom Formulations India Ltd Financial Statements
Comprehensive financial data for Syncom Formulations India Ltd including income statement, balance sheet and cash flow
About SYNCOMF (Syncom Formulations India Ltd)
Syncom Formulations India Ltd (SYNCOMF) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹1.46K (Cr). Syncom Formulations India Ltd has delivered a Return on Equity (ROE) of 15.50% and a ROCE of 18.59%. The debt-to-equity ratio stands at 0.00, reflecting the company's capital structure. Investors tracking SYNCOMF share price can monitor key metrics including P/E ratio, promoter holding of 50.57%, and quarterly earnings growth.
Company Details
Key Leadership
SYNCOMF Share Price: Frequently Asked Questions
What is the current share price of Syncom Formulations India Ltd (SYNCOMF)?
As of 17 Feb 2026, 10:24 am IST, Syncom Formulations India Ltd share price is ₹13.67. The SYNCOMF stock has a market capitalisation of ₹1.46K (Cr) on NSE/BSE.
Is SYNCOMF share price Overvalued or Undervalued?
SYNCOMF share price is currently trading at a P/E ratio of 23.28x, compared to the industry average of 31.77x. Based on this relative valuation, the Syncom Formulations India Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of SYNCOMF share price?
The 52-week high of SYNCOMF share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Syncom Formulations India Ltd share price?
Key factors influencing SYNCOMF share price include quarterly earnings growth (Sales Growth: 19.66%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Syncom Formulations India Ltd a good stock for long-term investment?
Syncom Formulations India Ltd shows a 5-year Profit Growth of 27.71% and an ROE of 15.50%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.00 before investing in SYNCOMF shares.
How does Syncom Formulations India Ltd compare with its industry peers?
Syncom Formulations India Ltd competes with major peers in the Pharmaceuticals. Investors should compare SYNCOMF share price P/E of 23.28x and ROE of 15.50% against the industry averages to determine competitive standing.
What is the P/E ratio of SYNCOMF and what does it mean?
SYNCOMF share price has a P/E ratio of 23.28x compared to the industry average of 31.77x. Investors pay ₹23 for every ₹1 of annual earnings.
How is SYNCOMF performing according to Bull Run's analysis?
SYNCOMF has a Bull Run fundamental score of 62.3/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does SYNCOMF belong to?
SYNCOMF operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Syncom Formulations India Ltd share price.
What is Return on Equity (ROE) and why is it important for SYNCOMF?
SYNCOMF has an ROE of 15.50%, which indicates excellent management efficiency. ROE measures how efficiently Syncom Formulations India Ltd generates profits from shareholders capital.
How is SYNCOMF debt-to-equity ratio and what does it indicate?
SYNCOMF has a debt-to-equity ratio of 0.00, which indicates conservative financing with low financial risk.
What is SYNCOMF dividend yield and is it a good dividend stock?
SYNCOMF offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Syncom Formulations India Ltd shares.
How has SYNCOMF share price grown over the past 5 years?
SYNCOMF has achieved 5-year growth rates of: Sales Growth 17.51%, Profit Growth 27.71%, and EPS Growth 23.05%.
What is the promoter holding in SYNCOMF and why does it matter?
Promoters hold 50.57% of SYNCOMF shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Syncom Formulations India Ltd.
What is SYNCOMF market capitalisation category?
SYNCOMF has a market capitalisation of ₹1463 crores, placing it in the Small-cap category.
How volatile is SYNCOMF stock?
SYNCOMF has a beta of N/A. A beta > 1 suggests the Syncom Formulations India Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is SYNCOMF operating profit margin trend?
SYNCOMF has a 5-year average Operating Profit Margin (OPM) of 11.41%, indicating the company's operational efficiency.
How is SYNCOMF quarterly performance?
Recent quarterly performance shows Syncom Formulations India Ltd YoY Sales Growth of 19.66% and YoY Profit Growth of 53.79%.
What is the institutional holding pattern in SYNCOMF?
SYNCOMF has FII holding of 0.10% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Syncom Formulations India Ltd stock.